HomeNDC LookupDrug shortages › Frovatriptan Succinate Tablet

Frovatriptan Succinate Tablet shortage

Frovatriptan Succinate Tablet is currently listed in shortage by the FDA. The FDA lists 2 affected products. This page was last refreshed from FDA data on Sep 22, 2026.

To Be Discontinued ⚠ Supply risk: High Neurology 2 products 315 days First posted Nov 12, 2025 Updated Feb 24, 2026
Here’s the bottom line

Endo Pharmaceuticals is permanently stopping production of frovatriptan succinate 2.5 mg tablets. Other makers have not reported a shortage, so the same medicine may still be available from other sources.

Don’t stop or change your therapy on your own — talk with your prescriber about the plan that fits you, and ask your pharmacist what’s actually available (see options).

Do you take this drug? See the ‘What to do’ recommendation from Dr. Brian Staiger, PharmD →
2
Affected NDCs
1
Reporting manufacturers
0/1
Reporting mfrs supplying
0/1
Affected strengths supplied
315
Days in shortage
Source: FDA Drug Shortages Database API (openFDA). Last refreshed Sep 22, 2026 · yesterday

What’s in shortage — at a glance

These figures count only the manufacturers that reported this shortage to the FDA — not every company that makes Frovatriptan Succinate Tablet. Other makers that haven’t reported a problem are shown in the green card below.

Availability of affected NDCs
From the FDA shortage report
2 NDCs
To be discontinued 2
Affected strengths still supplied
Among manufacturers reporting this shortage
0/1 strengths
No supply 1
FDA-reporting manufacturers with supply
Among manufacturers reporting this shortage
0/1 makers
No supply 1
✓ Other manufacturers not reporting a shortage
Still-marketed Frovatriptan Succinate Tablet from companies that have not filed an FDA shortage — these are not counted in the figures above. Stock can still vary by pharmacy.
Ingenus Pharmaceuticals, LLC Glenmark Pharmaceuticals Inc., USA Amneal Pharmaceuticals NY LLC
See all other options & details →
Shortage timeline
  1. Feb 24, 2026
    Currently in shortage
    2 of 2 products affected.
  2. Feb 24, 2026
    More presentations reported
    1 more product added to the shortage.
  3. Nov 12, 2025
    First reported to the FDA
    1 product first listed.

Built from FDA posting and update dates. The end date FDA publishes is the posting/update date, not a true resolution date, so durations are approximate.

What exactly is on backorder — by manufacturer

Manufacturer: Endo Pharmaceuticals, Inc. 📞 800-828-9393 2 NDCS click to expand
Status NDC / product Strength Availability Related information Reason
To Be Discontinued Frova, Tablet, 2.5 mg (NDC 63481-025-09) NDC 63481-0025-09 A business decision was made to discontinue manufacture of the drug.
To Be Discontinued Frova, Tablet, 2.5 mg (NDC 0603-3718-34) NDC 00603-3718-34 A business decision was made to discontinue manufacture of the drug.

These rows are manufacturer reports to the FDA for Frovatriptan Succinate Tablet — they do not necessarily cover every manufacturer that makes this drug. A company appears here only if it told the FDA it has a supply problem, so other makers may still have stock. That’s the basis for the Where else can I get Frovatriptan Succinate Tablet? options further down this page.

Why is Frovatriptan Succinate Tablet in shortage?

Endo Pharmaceuticals has made a business decision to permanently stop making Frova (frovatriptan succinate) 2.5 mg tablets. Both package sizes they carried — NDC 0603-3718-34 and NDC 63481-025-09 — are being discontinued. The FDA didn't receive a specific public explanation beyond it being a business decision on Endo's part, so unfortunately there's no more detail to share about the reasoning behind it.

It's worth knowing that this report only covers Endo Pharmaceuticals and their specific products. It does not mean frovatriptan is going away from every manufacturer — other companies may still produce it, and those would be listed separately.

Based on the manufacturer-reported reason(s) and notes on file with the FDA for Frovatriptan Succinate Tablet, summarized in plain English by HelloPharmacist. A drug can be short for more than one reason, and the FDA updates these as manufacturers report changes.

What should I do if I take Frovatriptan Succinate Tablet?

Frovatriptan succinate 2.5 mg tablets are currently on the FDA drug-shortage list, so I want to walk you through what this means for you.

The affected strength is the 2.5 mg tablet, which is the only strength involved here. At this time, the manufacturer that filed this report—Endo Pharmaceuticals, maker of the brand Frova—has no available supply of the 2.5 mg tablet. This is not because of a production problem; the reported reason is a business decision to discontinue making the drug. Because this is a discontinuation, this particular supply may not come back.

The important point is that other companies still make frovatriptan 2.5 mg tablets, so the medicine itself is not gone from the market.

Here is what I suggest:

  • Do not stop, skip, or change your dose on your own. Keep taking your medicine as prescribed.
  • Ask your pharmacy whether they can source frovatriptan 2.5 mg from another maker—the same medicine is available from Ingenus, Glenmark, and Amneal. It may not be in local stock, but your pharmacy can check.
  • If it cannot be found, talk with your prescriber or pharmacist about a suitable option.

Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle those calls. This reflects national data and may not match your local pharmacy's stock.

See “Where else can I get Frovatriptan Succinate Tablet?” below ↓ The same medicine from manufacturers not reporting a shortage, alternative dosage forms, and therapeutic equivalents with pricing.
If you are a patient:
  • Don’t stop or change the medication on your own — talk to your prescriber first.
  • If this is part of an ongoing or essential regimen (for example HIV treatment or prevention, seizure, heart, transplant, diabetes or mental-health medicines), do not skip or ration doses — contact your pharmacist or prescriber right away to arrange continued supply before you run out.
  • Ask your pharmacy to check other manufacturers, strengths, package sizes, and nearby stores.
  • Ask your prescriber whether a different strength, formulation, or the brand/generic version is appropriate.
Keep reading
Our full Frovatriptan guide

Uses, dosing, side effects, prices, and the complete FDA label — written in plain English and pharmacist-reviewed.

Read the Frovatriptan guide →

Where else can I get Frovatriptan Succinate Tablet?

FDA shortages are manufacturer-reported — a company only shows up on the shortage list if it told the FDA it has a supply problem, so not every maker of Frovatriptan Succinate Tablet is necessarily short. Below we pull together the other still-marketed options that are not reported in shortage: the same medicine from manufacturers that haven’t reported a problem, and alternative dosage forms. These may still be out of stock at your pharmacy, and only your prescriber or pharmacist can decide what’s right for you.

Same medicine, other manufacturers (not reported short)

Same active ingredient, dosage form & route as the shortage (matched on the FDB HICL ingredient code), from makers that have not filed a shortage with the FDA:

ProductStrengthForm / routeManufacturerNDC
Frovatriptan FROVATRIPTAN SUCCINATE 2.5 mg/1 Tablet, Film Coated · Oral Ingenus Pharmaceuticals, LLC 50742-0299-09
Frovatriptan Succinate FROVATRIPTAN SUCCINATE 2.5 mg/1 Tablet, Film Coated · Oral Glenmark Pharmaceuticals Inc., USA 68462-0694-97
Frovatriptan FROVATRIPTAN SUCCINATE 2.5 mg/1 Tablet, Film Coated · Oral Amneal Pharmaceuticals NY LLC 69238-1539-09
Therapeutic equivalents & pricing 5 productsclick to expand

Orange Book–rated equivalents of the affected strengths, with the latest NADAC price (a federal retail-acquisition benchmark, not your copay) and an evidence-based availability label. Cheapest first.

ProductManufacturerPackageNADAC $/unitAB ratingAvailability
Frovatriptan 2.5 mgNDC 50742-0299-09 Ingenus 9 tablets $2.781 save 14% AB Availability likely
frovatriptan succinate 2.5 mgNDC 68462-0694-97 Glenmark 9 tablets $2.781 save 14% AB Availability likely
Frovatriptan 2.5 mgNDC 69238-1539-09 Amneal 9 tablets $2.781 save 14% AB Availability likely
Frovatriptan Succinate 2.5 mgNDC 00603-3718-34 Par 9 tablets $3.251 Discontinued
Frova 2.5 mgNDC 63481-0025-09 Endo 9 tablets $136.033 Discontinued

Equivalents share the same ingredient, strength, dosage form and route; an AB rating means the FDA considers them substitutable. NADAC is a national retail-pharmacy acquisition benchmark from CMS — not what you pay. Availability is inferred from recent pricing, not a stock check.

Other drugs in the same treatment class

These are different medicines — not other versions of Frovatriptan Succinate Tablet — that fall in the same broad treatment class (antimigraine preparations) . They are not automatic substitutes: they can differ in how they work, dosing, effectiveness, side effects and what they’re approved to treat. Do not switch on your own. This list is for information only — ask your prescriber or pharmacist whether any of them is appropriate for you.

Identity & classification

GCN Seq No 048986
GCN 14977
HICL code 022988
Ingredient (HICL) Frovatriptan Succinate
HIC1 code H
Therapeutic class — broad (HIC1) Nervous System (Except Autonomic)
HIC2 code H3
Therapeutic class — intermediate (HIC2) Analgesics
HIC3 code H3F
Therapeutic class — specific (HIC3) Antimigraine Preparations
AHFS code 28:32.28.00
AHFS class Selective Serotonin Agonists
FDB label name FROVA 2.5 MG TABLET
FDB brand name Frova
Legend status F — Federal legend — prescription drug or device
Where does this data come from?
Identity codes come from First Databank (FDB) (HICL ingredient, HIC1–3 therapeutic-class hierarchy, GCN, AHFS class, legend status) and Medi-Span GPI, mapped from a representative affected NDC. Licensed reference data — for identification only.

Other neurology shortages

Frovatriptan Succinate Tablet shortage FAQs

Is Frovatriptan Succinate Tablet in shortage?
Yes — the FDA currently lists Frovatriptan Succinate Tablet in shortage (status: “To Be Discontinued”, first reported Nov 12, 2025). 2 of 2 products are affected. This is national, manufacturer-reported data, so your pharmacy may still have stock.
Which products are affected?
Frova, Tablet, 2.5 mg (NDC 63481-025-09) (NDC 63481-0025-09); Frova, Tablet, 2.5 mg (NDC 0603-3718-34) (NDC 00603-3718-34). The full per-NDC list (availability, manufacturer and status) is in the table above — each NDC links to its own page.
When will Frovatriptan Succinate Tablet be available again?
The FDA does not publish a guaranteed restock date, and no estimated-recovery note is on file. Availability can change daily — confirm with your pharmacy.
Can I still get Frovatriptan Succinate somewhere?
Other manufacturers (Ingenus Pharmaceuticals, LLC, Glenmark Pharmaceuticals Inc., USA, Amneal Pharmaceuticals NY LLC) still market it and have not reported a shortage. See “Where else can I get Frovatriptan Succinate Tablet?” above — stock still varies by pharmacy.
What should I do if I take Frovatriptan Succinate Tablet?
Don’t stop or change it on your own. Ask your pharmacist whether they can order it from another manufacturer or a different strength/package size, and ask your prescriber about a long-term plan before your supply runs out.

Still have a question about the Frovatriptan Succinate Tablet shortage?

Ask a pharmacist about this shortage →
How to read the Supply-Risk rating
Low (1–2)Multiple manufacturers still supplying and most strengths or pack sizes sourceable.
Medium (3)Some constraint — fewer suppliers or a notable share of NDCs unavailable.
High (4–5)Down to a single source, most strengths or pack sizes unsourceable, or a long-running outage.
Where does this data come from?
Shortage records come from the FDA Drug Shortages Database API via openFDA (/drug/shortages) — drug, manufacturer & contact, NDC/product, status, availability, reason, therapeutic category and posting/update dates. Current / To Be Discontinued = active; Resolved is kept for history. The Supply-Risk rating is assessed per active ingredient and adds the FDA NDC Directory (still-marketed manufacturers by ingredient & form); same-medicine and equivalent products use First Databank classification + CMS NADAC pricing; Medicaid use + most-affected states come from CMS Medicaid State Drug Utilization Data. Reference only — confirm current status with the manufacturer or FDA before acting on it.
Data structure & sourcing designed and verified by Dr. Brian Staiger, PharmD.
← Back to all current drug shortages